| Identification | Back Directory | [Name]
Integrin-IN-2 | [CAS]
2378617-67-3 | [Synonyms]
Integrin-IN-2
Integrin IN 2,IntegrinIN2
Benzenepropanoic acid, 3-cyclopropyl-β-[[5-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-2-pyridinyl]amino]- | [Molecular Formula]
C27H30N4O3 | [MDL Number]
MFCD32263429 | [MOL File]
2378617-67-3.mol | [Molecular Weight]
458.55 |
| Hazard Information | Back Directory | [Uses]
Integrin-IN-2 (compound 39) is an orally bioavailable pan αv integrin inhibitor. Integrin-IN-2 can increases the αvβ6, αvβ3, αvβ5 and αvβ8 binding affinities with pIC50 values of 7.8, 8.4, 8.4 and 7.4, respectively[1]. | [in vivo]
In vivo pharmacokinetic studies in CD rats revealed that racemic Integrin-IN-2 (compound 39) has a low plasma clearance of 8 mL/(min kg), a low to moderate volume of distribution of 0.5 L/kg, a moderate halflife of 1.8 h, and very high bioavailability of 98%[1]. | [References]
[1] Anderson NA, et al. Discovery of an Orally Bioavailable Pan αv Integrin Inhibitor for Idiopathic Pulmonary Fibrosis. J Med Chem. 2019 Oct 10;62(19):8796-8808. DOI:10.1021/acs.jmedchem.9b00962 |
|
|